Mr. Stonebanks is the Founder & Managing Partner of Blackcomb Advisors. Blackcomb Advisors is a global advisory firm providing investing, due diligence, Board support, fund raising, M&A, licensing and strategic commercial & R&D advisory / partnership services to small and large companies, private equity, investment banking and private and public investment funds in life sciences, health care and information technology.
He is also VP and Chief Commercial Officer for OICR. (Ontario Institute for Cancer Research). He leads the Institute's commercialization program including managing its investment fund, identifying and developing opportunities to collaborate with private equity and corporate strategic investors in oncology; spearheads the intellectual property program to maximize OICR's extensive intellectual property pipeline, and identifies and accelerates transformative early stage research and development projects using novel business models.
OICR is an innovative cancer research & development institute dedicated to translational research in prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation, with 1500 people in R&D and a $160 mm annual operating budget. It has key research efforts underway in small molecules, biologics, stem cells, imaging, genomics, informatics and bio-computing, as well as significant partnerships with major pharma and private equity firms to enhance early stage innovation and product development.
Mr. Stonebanks was previously President & CEO of Cynvec LLC, an early stage biotech company spun out of New York University, where he raised bridge financing, developed the companys positioning and strategy and led them through the IND process at the FDA. Prior to becoming Cynvec's CEO, Mr. Stonebanks was a Senior Advisor for IBM, leading their global healthcare & life science M&A efforts and advising the company on its healthcare and life science strategy. He also co-managed their $500 mm venture fund, an LP in more than 30 venture capital firms globally. He was previously Vice President and General Manager at Johnson & Johnson, where he was also Co-Founder & CEO of the Macroflux Corporation (now Zosano Pharma), a J&J corporate spinoff of a drug delivery platform, that had multiple products in Phase I and II studies. Mr. Stonebanks raised over $100 mm in equity financing to facilitate the spin off.
Mr. Stonebanks was previously founder, Executive Director and leader of the Oncology Biologics Business Unit at Centocor, a unit in the Global Marketing group that integrated marketing, medical affairs, market research and health outcomes. Mr. Stonebanks also led the global marketing infectious disease biologics efforts for Centocor / J&J.
During his career Mr. Stonebanks has completed more than a dozen deals ranging in size from $2 mm to $5B, facilitated the acceleration of new products and led domestic and global launches and commercial strategy for the last 18 years across multiple therapeutic areas, holding senior posts at Hoechst Marion Roussel, Rhone Poulenc Rorer (Aventis), Nabi Biopharmaceuticals, Johnson & Johnson and IBM in the areas mergers and acquisitions, venture investing, business & corporate development, domestic and global marketing and general management.
Mr. Stonebanks has also served as an Advisor to Kleiner Perkins Caulfield Byers, Silver Lake, and several other hedge and family funds.
Mr. Stonebanks completed his undergraduate degree in Exercise Physiology at the University of Victoria, B.C., Canada and his M.B.A. in Pharmaceutical Marketing at St. Josephs University in Philadelphia. Mr. Stonebanks also holds a diploma from the Amos Tuck School of Business Administration (Dartmouth) in Pharmaceutical Marketing. He is a member of the National Venture Capital Association, ASCO and AACR.
